ORIGINAL RESEARCH article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1577344
This article is part of the Research TopicInnovative Strategies in Overcoming Glioblastoma: Advancements in Treatment and ResearchView all 6 articles
Candidate gene mutations of patients with astrocytoma who present with seizures: Evidence from whole exome sequencing
Provisionally accepted
Kanitpong Phabphal1,2*
Pongsakorn Choochuen2Anukoon Kaewborisutsakul2Thara Tunthanathip2
Surasak Sangkhathat2- 1Prince of Songkla University, Songkhla, Thailand
- 2Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Epileptic seizures are common and substantially impact long-term quality of life. However, the risk factors for preoperative seizures among patients with astrocytomas remain unclear. This study aimed to identify the candidate genes associated with seizure before operation among patients with astrocytomas. We conducted a single-center cohort study including 34 patients with astrocytomas that presented with or without preoperative seizures and analyzed differential gene expression, evaluating a total of 142 candidate genes, selected based on a literature review, and categorized into functional groups (e.g., glutamatergic, oncogenic, chromatin-modifying). Clinical characteristics, including age, sex, tumor location, grade, and size, and peritumoral edema, were similar between the seizure and non-seizure groups.Glutamate receptor mutations were identified in 15% of the non-seizure group and 78.6% of the seizure group. Patients with astrocytomas who presented with seizures had significantly more mutations in glutamate-related genes, including NMDA (64.3% vs. 20%, p = 0.01) and IDH1 (42.7% vs. 10%, p = 0.04). Group III metabotropic glutamate receptor alterations were found in 1 patient in the non-seizure group (n = 19) and in 5 patients in the seizure group (n = 9) (p = 0.06). No significant differences were observed in other glutamate receptors subtypes or related genes. In conclusion, seizures in patients with astrocytomas are associated with IDH1 and NMDA receptor mutations, rather than other clinicopathological factors or other glutamate-related genes. Future research should involve larger multicenter studies and conduct a functional analysis to identify new treatment targets and provide additional evidence to guide clinical decision-making.
Keywords: Astrocytoma, seizure, NMDA, IDH1, Glutamate
Received: 15 Feb 2025; Accepted: 19 Jun 2025.
Copyright: © 2025 Phabphal, Choochuen, Kaewborisutsakul, Tunthanathip and Sangkhathat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kanitpong Phabphal, Prince of Songkla University, Songkhla, Thailand
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.